Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip M Arlen

Showing results (1-10 of 88) with videos related to

Pageof 9
Sort By:
Expert Review of Vaccines|March 19, 2013
Prostate cancer vaccines: an old yet novel target, the androgen receptorPhilip M Arlen
Idrugs : the Investigational Drugs Journal|December 24, 2005
Abiraterone. Cougar BiotechnologyRavi A Madan, Philip M Arlen
Current Opinion in Investigational Drugs (London, England : 2000)|July 2, 2005
Therapeutic vaccines for prostate cancer: a review of clinical dataPhilip M Arlen, James L Gulley
Future Oncology (London, England)|March 25, 2006
Docetaxel-based regimens, the standard of care for metastatic androgen-insensitive prostate cancerPhilip M Arlen, James L Gulley
Future Oncology (London, England)|August 2, 2013
Recent advances revolutionize treatment of metastatic prostate cancerRavi A Madan, Philip M Arlen
Anti-Cancer Agents in Medicinal Chemistry|September 2, 2009
Current perspectives in prostate cancer vaccinesPhilip M Arlen, James L Gulley
Expert Review of Vaccines|March 3, 2012
Prostate cancer vaccines: moving therapeutic vaccination forward in the post-Provenge eraPhilip M Arlen, Lauren V Wood
Journal of Biomedicine & Biotechnology|January 4, 2011
Development of a serum biomarker assay that differentiates tumor-associated MUC5AC (NPC-1C ANTIGEN) from normal MUC5ACJanos Luka, Philip M Arlen, Andrew Bristol
American Journal of Therapeutics|May 11, 2004
Vaccine therapy for a patient with androgen-insensitive prostate cancer without evidence of measurable disease on scansPhilip M Arlen, James L Gulley, William Dahut
Experimental Biology and Medicine (Maywood, N.J.)|April 1, 2008
Paradigm shifts in cancer vaccine therapyJeffrey Schlom, James L Gulley, Philip M Arlen
Pageof 9

Showing results (1-10 of 88) with videos related to

Sort By:
Pageof 9
Expert Review of Vaccines|March 19, 2013
Prostate cancer vaccines: an old yet novel target, the androgen receptorPhilip M Arlen
Idrugs : the Investigational Drugs Journal|December 24, 2005
Abiraterone. Cougar BiotechnologyRavi A Madan, Philip M Arlen
Current Opinion in Investigational Drugs (London, England : 2000)|July 2, 2005
Therapeutic vaccines for prostate cancer: a review of clinical dataPhilip M Arlen, James L Gulley
Future Oncology (London, England)|March 25, 2006
Docetaxel-based regimens, the standard of care for metastatic androgen-insensitive prostate cancerPhilip M Arlen, James L Gulley
Future Oncology (London, England)|August 2, 2013
Recent advances revolutionize treatment of metastatic prostate cancerRavi A Madan, Philip M Arlen
Anti-Cancer Agents in Medicinal Chemistry|September 2, 2009
Current perspectives in prostate cancer vaccinesPhilip M Arlen, James L Gulley
Expert Review of Vaccines|March 3, 2012
Prostate cancer vaccines: moving therapeutic vaccination forward in the post-Provenge eraPhilip M Arlen, Lauren V Wood
Journal of Biomedicine & Biotechnology|January 4, 2011
Development of a serum biomarker assay that differentiates tumor-associated MUC5AC (NPC-1C ANTIGEN) from normal MUC5ACJanos Luka, Philip M Arlen, Andrew Bristol
American Journal of Therapeutics|May 11, 2004
Vaccine therapy for a patient with androgen-insensitive prostate cancer without evidence of measurable disease on scansPhilip M Arlen, James L Gulley, William Dahut
Experimental Biology and Medicine (Maywood, N.J.)|April 1, 2008
Paradigm shifts in cancer vaccine therapyJeffrey Schlom, James L Gulley, Philip M Arlen
Pageof 9